(Reuters) – Finnish drug maker Orion on Wednesday raised its full year outlook after it signed a collaboration agreement with Merck aimed at developing a prostate cancer drug candidate.
Given the upfront payment of $290 million Orion is to receive from Merck, the Finnish company now expects sales and operating profit in 2022 to be “clearly higher” than in 2021.
(Reporting by Boleslaw Lasocki; editing by Jason Neely)
